| Literature DB >> 29674364 |
Changhyun Lee1, Eun Kyung Choe1, Sue Kyung Park2,3,4, Sang-Heon Cho1, Ji Min Choi1, Yunji Hwang2,3,4, Young Lee1, Boram Park1, Su Jin Chung1, Min-Sun Kwak1, Jong-Eun Lee5, Joo Sung Kim1.
Abstract
PURPOSE: The Health and Prevention Enhancement (H-PEACE) study was designed to investigate the association of diagnostic imaging results, biomarkers and the predisease stage of non-communicable diseases (NCDs), such as malignancies and metabolic diseases, in an average-risk population in Korea. PARTICIPANTS: This study enrolled a large-scale retrospective cohort at the Healthcare System Gangnam Center, Seoul National University Hospital, from October 2003 to December 2014. FINDINGS TO DATE: The baseline and follow-up information collected in the predisease stage of NCDs allows for evaluation of an individual's potential NCD risk, which is necessary for establishing personalised prevention strategies. A total of 91 336 health examinees were included in the cohort, and we repeatedly measured and collected information for 50.9% (n=46 484) of the cohort members. All participants completed structured questionnaires (lifestyle, medical history, mini-dietary assessment index, sex-specific variables and psychiatric assessment), doctors' physical examinations, laboratory blood and urine tests and digital chest X-ray imaging. For participants with available data, we also obtained information on specific diagnostic variables using advanced diagnostic tests, including coronary CT for coronary calcium scores, colonoscopy and brain MRI. Furthermore, 17 455 of the participants who provided informed consent and donated blood samples were enrolled into the Gene-environmental interaction and phenotype study, a subcohort of the H-PEACE, from October 2013, and we analysed genome-wide single-nucleotide polymorphism array data for 6579 of these blood samples. FUTURE PLANS: The data obtained from this cohort will be used to facilitate advanced and accurate diagnostic techniques related to NCDs while considering various phenotypes. Potential collaborators can access the dataset after receiving approval from our institutional review board. Applications can be submitted on the study homepage (http://en-healthcare.snuh.org/HPEACEstudy). © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: cohort; epidemiology; non-communicable disease; preventive medicine
Mesh:
Year: 2018 PMID: 29674364 PMCID: PMC5914782 DOI: 10.1136/bmjopen-2017-019327
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Study flow diagram of the Health and Prevention Enhancement study.GC, Gangnam Center; GWAS, genome-wide association study; SNUH, Seoul National University Hospital.
Figure 2Regional distribution of the Health and Prevention Enhancement study in Korea.
Participation rate for the core and specific variables collected in the Health and Prevention Enhancement (H-PEACE) study at baseline
| Variables | Study | Participation |
| Core variables | ||
| Most core variables | ≥90 377 | ≥99 |
| ECG | 91 197 | 99.8 |
| Estimated GFR | 91 197 | 99.8 |
| Stool parasite examination | 82 493 | 90.3 |
| | 81 142 | 88.8 |
| Thyroid function test | 77 313 | 84.6 |
| CLO test or UBT test for current | 67 986 | 74.4 |
| Gastroendoscopy with pathological report | 66 451 | 72.8 |
| Specific variables | ||
| Dental examination | 43 232 | 47.3 |
| Colonoscopy with pathological reports | 46 050 | 50.4 |
| Abdomen CT with visceral fat CT | 34 771 | 38.1 |
| Abdomen sonography | 33 446 | 36.6 |
| Echocardiography | 20 688 | 22.7 |
| Coronary CT | 12 846 | 14.1 |
| Echocardiography, treadmill test | 9910 | 10.9 |
| SNP from GWAS | 6579 | 7.2 |
| Bone densitometry (postmenopausal females) | 26 376 | 99.4 |
| E2 levels (postmenopausal females after 5 years from menopause) | 4742 | 49.9 |
| Bone densitometry (men≥50 years) | 9488 | 48.9 |
| T levels (men≥60 years) | 6697 | 52.9 |
| HPV genotyping (females) | 12 999 | 31.8 |
| Pap smear (women≥35 years) | 12 951 | 49.1 |
| Blood collection for the GENIE study | 17 455 | 19.1 |
| SNP variations in the GWAS | 6579 | 37.7† |
*Participation rate of all 91 336 H-PEACE cohort members.
†Participation rate of all 17 455 GENIE study members (a subcohort of the H-PEACE study).
CLO, Campylobacter-like organism; GENIE, Gene-environmental interaction and phenotype; GFR, glomerular filtration rate; GWAS, genome-wide association study; HPV, human papillomavirus; SNP, single-nucleotide polymorphism; UBT, urea breath test.
Figure 3Flow diagram of health check-ups in the Health and Prevention Enhancement study. CLO, Campylobacter-like organism; DEXA, dual-energy X-ray absorptiometry; MRA, magnetic resonance angiogram; VDRL, venereal disease research laboratory
Core variables collected at baseline and follow-up in the Health and Prevention Enhancement study from 2003 to 2014
| Item | List | |
| Self-record questionnaires |
Demographic and lifestyles questionnaire: socioeconomic variables, including education, household income, marital status and occupation; medical history of diabetes, hypertension, dyslipidaemia and cancer; family history of diabetes, hypertension, dyslipidaemia and cancer in first relatives; alcohol consumption and cigarette smoking Physical activity: Korea-validated version of the International Physical Activity Questionnaire short form Dietary factors: Mini-Dietary Assessment Index Sex-specific questionnaire: International Prostate Symptom Score and the International Index of Erectile Function for men; reproductive factors for women, including menstrual history (age at menarche, length and regularity of menstrual cycle), menopausal status and age, pregnancy history (including the number/methods of pregnancies and abortions) and breast feeding Psychiatric assessment questionnaire: Beck Depression Inventory and Quick Inventory of Depressive Symptomatology-Self Report | |
| Anthropometric measurements and physical examination |
Systolic and diastolic blood pressure Height, weight and waist circumference Body composition using a multifrequency bioimpedance analyser Physical examination by physician Eye examination, including visual acuity, ocular tonometry and slit-lamp test by ophthalmologist Fundus photography (persons≥35 years) by ophthalmologist Hearing test (persons≥50 years) by otolaryngologist | |
| Laboratory blood tests |
Complete blood cell count (WBC, RBC and platelet count, haemoglobin, haematocrit) Coagulation profiles (PT, PT-INR, aPTT) Diabetes profiles (fasting glucose, haemoglobin A1c) Liver function profiles (protein/albumin, AST/ALT/gamma-GTP, total bilirubin) Kidney function profiles (BUN, creatinine) Electrolytes (calcium, phosphate, sodium, potassium, chloride, total CO2) Lipid profiles (total cholesterol, triglycerides, LDL/HDL cholesterol levels) Uric acid | |
| Urine tests |
Protein, glucose, ketone, bilirubin, blood and pH | |
| Stool exams |
Occult blood in stool, parasite assay | |
| Infections and inflammation markers |
HBsAg, anti-HBs, anti-HCV HAV Ab IgG (persons<50 years) |
VDRL (Rapid Plasma Reagin Card Test) HIV Ag/Ab combo test Hs-CRP |
| Hormones |
Thyroid function tests (TSH, T3, total-T4, free-T4) | |
| Tumour markers |
AFP, CEA CA19-9 |
CA-125 (all females) PSA (men≥35 years) |
| Other clinical tests |
Chest X-ray (digital imaging) Pulmonary function test ECG Gastroendoscopy with pathological reports |
Pap smear and gynaecological examination (women≥35 years) Mammography (women≥35 years) |
AFP, alpha-fetoprotein; ALT, alanine transaminase; anti-HBs, anti-hepatitis B surface antibody; anti-HCV, anti-hepatitis C antibody; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; BUN, blood urea nitrogen; CA-125, cancer antigen 125; CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; GTP, gamma-glutamyl transferase; HBsAg, hepatitis B surface antigen; Helicobacter pylori IgG Ab, hepatitis A IgG antibody; HDL, high-density lipid; Hs-CRP, high-sensitivity C reactive protein; INR, International Normalized Ratio; LDL, low-density lipid; PSA, prostate-specific antigen; PT, prothrombin time; RBC, red blood cell; TSH, thyroid-stimulating hormone; VDRL, venereal disease research laboratory; WBC, white blood cell.
Baseline characteristics of the participants in the Health and Prevention Enhancement study
| Total | Men | Women | P values | |
| n (%) | n (%) | n (%) | ||
| Age (years) | <0.001 | |||
| <35 | 16 228 (17.8) | 7666 (15.2) | 8562 (21.0) | |
| 35–44 | 26 963 (29.5) | 15 139 (30.0) | 11 824 (29.0) | |
| 45–54 | 27 915 (30.6) | 15 776 (31.2) | 12 139 (29.7) | |
| 55–64 | 14 937 (16.4) | 8717 (17.3) | 6220 (15.2) | |
| 65+ | 5293 (5.8) | 3209 (6.4) | 2084 (5.1) | |
| Sex | ||||
| Men | 50 509 (55.3) | |||
| Women | 40 827 (44.7) | |||
| Cigarette smoking status | <0.001 | |||
| Non-smokers | 48 521 (53.1) | 11 779 (23.3) | 36 742 (90.0) | |
| Ex-smokers | 22 564 (24.7) | 20 469 (40.5) | 2095 (5.1) | |
| Current smokers | 20 251 (22.2) | 18 259 (36.2) | 1992 (4.9) | |
| Regular exercise | <0.001 | |||
| Inactive | 36 343 (39.8) | 17 843 (35.3) | 18 500 (45.3) | |
| Minimally active | 26 189 (28.7) | 16 428 (32.5) | 9761 (23.9) | |
| HEPA | 28 804 (31.5) | 16 236 (32.1) | 12 568 (30.8) | |
| Excess alcohol drinking (>140 g/week) | 20 421 (22.3) | 18 934 (37.5) | 1469 (3.6) | <0.001 |
| Education≥high school graduate | 78 821 (86.3) | 45 538 (90.2) | 33 283 (81.5) | <0.001 |
| Hypertension | 13 279 (14.5) | 9003 (17.8) | 4276 (10.5) | <0.001 |
| Diabetes | 4377 (4.8) | 3181 (6.3) | 1196 (2.9) | <0.001 |
| Current HBsAg+ | 3810 (4.2) | 2377 (4.7) | 1433 (3.5) | <0.001 |
| Current anti-HCV+ | 887 (0.97) | 492 (0.97) | 395 (0.97) | 0.946 |
*Visceral fat area is defined here as the cross-sectional area of visceral fat found in the abdomen.
Anti-HCV, anti-hepatitis C antibody; DBP, diastolic blood pressure; HBsAg, hepatitis B surface antigen; HDL, high-density lipid; HEPA, health-enhancing physically active; Hs-CRP, high-sensitivity C reactive protein; LDL, low-density lipid; SBP, systolic blood pressure.
Morbidity rates after active follow-up with specific measurements in the Health and Prevention Enhancement study
| Test | Definition | Participants tested | Follow-up years | Clinical finding* | |
| Coronary calcification |
Coronary artery calcium score>400 at coronary CT | 12 846 | 5.6 (3.2–8.0) | 805 | |
| Atrial fibrillation |
ECG and/or ambulatory ECG | 91 076 | 4.1 (2.1–6.5) | 446 | |
| Left bundle branch block |
ECG and/or ambulatory ECG | 91 076 | 4.1 (2.1–6.5) | 64 | |
| Chronic kidney disease |
Estimated GFR†<60 mL/min/1.73 m2 | 91 197 | 4.0 (2.1–6.5) | 5372 | |
| Visceral obesity |
Men>10 000 cm2, Women>8000 cm2 in abdomen visceral fat CT | 34 771 | 5.0 (3.0–7.4) | 23 126 | |
| Fatty liver |
Abdominal sonography and/or abdominal CT | 34 771 | 5.0 (3.0–7.4) | Mild | 10 244 |
| Moderate | 5963 | ||||
| Severe | 688 | ||||
| Abnormal thyroid function |
Thyroid hormone measurement | 77 313 | 4.1 (2.2–6.6) | Hypothyroidism | 363 |
| Hyperthyroidism | 1260 | ||||
|
|
| 81 142 | 4.2 (2.3–6.7) | 44 304 | |
| High-risk HPV infection |
HPV 16, 18 positive finding in HPV genotyping | 12 999 | 5.0 (3.1–7.2) | 1462 | |
| Parasite infection |
Stool examination | 82 493 | 4.1 (2.2–6.6) |
| 1262 |
|
| 124 | ||||
|
| 256 | ||||
|
| 412 | ||||
| Premalignant conditions of stomach |
Gastroendoscopy with pathological reports | 66 451 | 4.2 (2.3–6.7) | Atrophic gastritis | 23 896 |
| Intestinal metaplasia | 10 187 | ||||
| Malignant gastric cancer |
Gastroendoscopy with pathological reports | 66 451 | 4.2 (2.3–6.7) | 299 | |
| SIL |
Pap smear and pathological report | 12 951 | 5.0 (3.1–7.2) | Total SIL | 375 |
| Low grade | 315 | ||||
| High grade | 60 | ||||
| Premalignant colonic neoplasms |
Colonoscopy with pathological reports | 46 746 | 4.8 (2.9–7.1) | Adenoma | 18 656‡ |
| Serrated polyp | 1178‡ | ||||
| Carcinoid | 150 | ||||
| Malignant colon cancer |
Colonoscopy with pathological reports | 46 746 | 4.8 (2.9–7.1) | 262 | |
| Low bone density |
Bone densitometry | 35 695 | 4.8 (2.9–7.2) | Osteopenia | 2322 |
| Osteoporosis | 305 | ||||
| Periodontitis |
Dental examination | 43 232 | 4.9 (2.8–7.2) | Total periodontitis | 15 204 |
| Mild to moderate | 14 292 | ||||
| Severe | 912 | ||||
*The number of findings among the participants who were at risk.
†The GFR was estimated by the Chronic Kidney Disease Epidemiology Collaboration equation and the Modification of Diet in Renal Disease formula.
‡Adenoma and serrated polyp detection rate were calculated in participants aged 50–75 years.
CLO, Campylobacter-like organism; GFR, glomerular filtration rate; HPV, human papillomavirus; SIL, squamous intraepithelial lesion; UBT, urea breath test.
Major cancer incidence and outcomes based on record linkage to the Nationwide Death Certificate Database in the Health and Prevention Enhancement (H-PEACE) study*
| Cancer incidence (n) | All-cause death† (n) | |||||
| Total | Men | Women | Total | Men | Women | |
| Total cancer | 2814 | 1402 | 1412 | 207 | 150 | 57 |
| Thyroid | 956 | 390 | 566 | 3 | 3 | 0 |
| Stomach | 513 | 337 | 176 | 37 | 29 | 8 |
| Breast | 343 | 1 | 342 | 6 | 0 | 6 |
| Colorectal | 284 | 182 | 102 | 28 | 20 | 8 |
| Lung | 186 | 109 | 77 | 45 | 32 | 13 |
| Prostate | 127 | 127 | 0 | 3 | 3 | 0 |
| Kidney | 91 | 71 | 20 | 1 | 1 | 0 |
| Liver | 87 | 71 | 16 | 31 | 28 | 3 |
| Gynaecology | 52 | 0 | 52 | 7 | 0 | 7 |
| Pancreas | 42 | 25 | 17 | 27 | 19 | 8 |
| Brain | 39 | 20 | 19 | 0 | 0 | 0 |
| Haematological | 39 | 24 | 15 | 5 | 3 | 2 |
| Biliary tract | 32 | 26 | 6 | 11 | 9 | 2 |
| Oesophagus | 23 | 19 | 4 | 3 | 3 | 0 |
*Median (IQR) follow-up years of the 91 336 participants=4.04 (2.13–6.5).
†Since the Nationwide Death Certificate Database does not provide information about cause of death, number of death includes death from not only cancer but also other causes. Among the 91 336 H-PEACE participants, the all-cause mortality rate was 969: 715 men and 254 women.
Specific variables* collected at baseline and follow-up in the Health and Prevention Enhancement (H-PEACE) study
| Specific items | List | |
| SNP |
SNP variation by genome-wide SNP arrays (Affymetrix platform of Axiom Customized Genome-Wide Human Assay)† | |
| Heart |
Coronary calcium score CT Echocardiography, treadmill test |
Coronary CT angiography Holter monitoring |
| Stroke |
Lp (a) lipoprotein (a), homocysteine Echocardiography, carotid Doppler |
Brain MRI Brain and carotid MRA |
| Kidney |
24-hour urinary uric acid, creatinine, urea nitrogen, protein and microalbumin 24-hour urinary electrolytes including sodium, potassium, calcium, phosphorus and magnesium 24-hour urinary citrate and oxalate |
Serum cystatin C Dynamic kidney CT |
| Intestine |
Abdominal sonography Colonoscopy with pathological reports |
Abdomino-pelvic CT |
| Obesity |
24-hour recall diet questionnaire Serum insulin levels |
Abdomen and thigh CT (for visceral fat) Whole-body DEXA |
| Dementia |
Apo-E genotyping MR double time |
Brain MRI, brain MRA, hippocampus (non-contrast) |
| Prostate |
Free PSA Uroflowmetry Ultrasonography (for residual urine) |
Transrectal sonography Prostate MRI (non-contrast) |
| Sex hormones |
Testosterone (men≥60 years) Total and free E2, LH, FSH (postmenopausal women after 5 years from menopause) | |
| Cigarette smoking |
CO levels in exhalation, urine cotinine levels Laryngoscopy, low-dose screening chest CT | |
| Bone |
Bone densitometry (men≥50 years and postmenopausal women) Site-specific X-ray digital imaging (AP and Lat.) Site-specific bone CT | |
| Dental |
Dental, peridental and periodontal examination | |
| Nutrition |
Plasma vitamin B6 profile (pyridoxal phosphate, pyridoxic acid) Plasma vitamin A and E (HPLC) |
Plasma 25(OH)D Vitamin C, B12 and folate levels Serum selenium, zinc, copper levels |
| Allergy |
Multiple IgE (PRIST) Skin prick test (inhalant) |
Methacholine bronchial c Histograms of categorised shapes ear detection |
| Hepatitis |
HBV viral load, HBeAg (quantitation), HBeAb HCV PCR |
Liver fibrosis scan |
| Heavy mineral |
Cd, Pb, Hg, As, Al, Se, Cu, Zn, Cr, Co, Mn, Mo | |
| Other |
HPV genotyping CLO test or UBT test for current | |
*The specific variables were selected for the health screenees according to the specific test or physician’s request.
†GWAS genotyping was performed among the 17 455 cohort participants who provided informed consent and donated blood samples. We categorised the 17 455 participants with blood specimens as the Gene-environmental interaction and phenotype study (a specific subcohort derived from the H-PEACE study). SNP testing was performed for research purposes and was not a routinely performed test.
CLO, Campylobacter-like organism; DEXA, dual-energy X-ray absorptiometry; GWAS, genome-wide association study; FSH, follicle-stimulating hormone; HPLC, high-performance liquid chromatography; HPV, human papillomavirus; LH, luteinising hormone; MRA, magnetic resonance angiogram; PRIST, paper radioimmunosorbent test, PCR, polymerase chain reaction; PSA, prostate-specific antigen; SNP, single-nucleotide polymorphism; UBT, urea breath test.